SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-21-012463
Filing Date
2021-04-12
Accepted
2021-04-12 17:02:23
Documents
9
Period of Report
2021-05-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A nc10022480x2_def14a.htm DEF 14A 1190212
2 logo_seelostherapeutics.jpg GRAPHIC 35790
3 nc10022480x2_annexbimg01.jpg GRAPHIC 1046900
4 nc10022480x2_annexbimg02.jpg GRAPHIC 920019
5 nc10022480x2_annexbimg03.jpg GRAPHIC 948688
6 nc10022480x2_annexbimg04.jpg GRAPHIC 867652
7 nc10022480x2_pc1x1.jpg GRAPHIC 635764
8 nc10022480x2_pc2x1.jpg GRAPHIC 613102
9 sig_rajmehra.jpg GRAPHIC 14562
  Complete submission text file 0001140361-21-012463.txt   8189063
Mailing Address 300 PARK AVENUE NEW YORK NY 10017
Business Address 300 PARK AVENUE NEW YORK NY 10017 (646) 998-6475
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22245 | Film No.: 21821311
SIC: 2834 Pharmaceutical Preparations